Call our 24 hours, seven days a week helpline at 800.272.3900

24/7 Helpline 800.272.3900

Alzheimer’s Association Statement Biogen Report of Phase 3 Aducanumab Data at CTAD 2019

Alzheimer’s Association Statement Biogen Report of Phase 3 Aducanumab Data at CTAD 2019
Share or Print this page
Share or Print this page
December 5, 2019
Email:, 312-335-4078

Niles Frantz,, 312-363-8782
MJ Contino,, 872-225-3974
Share or Print this page
Attributable to Maria C. Carrillo, Ph.D. Alzheimer’s Association chief science officer.
CHICAGO, December 5, 2019 — This is an important moment for the Alzheimer’s field. We’ve recently learned that, for the first time in more than a decade, new treatment data will be submitted to the U.S. FDA for review. On behalf of the more than 5 million Americans living with Alzheimer’s and their families we serve and represent, the Alzheimer’s Association looks forward to learning the results of that review.
The Alzheimer's Association has always been a champion for those affected by Alzheimer’s and their families, and an advocate for access to treatments, when they become available. If the FDA approves this drug for the treatment of Alzheimer’s, our expectation is that everyone for whom the drug was demonstrated to be beneficial will have access to treatment as soon as possible.
No stone can be left unturned. The Alzheimer’s Association believes we must advance all potential treatment avenues, and explore methods for combining approaches that are proven to be successful.

Alzheimer's Association

The Alzheimer's Association is the leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer's. For more information, visit

Keep Up With Alzheimer’s News and Events